Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogs is an approved, effective treatment for neuroendocrine tumors that improves survival and quality of life.
FDA approved 2017-2018177Lu-DOTATATE became the first approved peptide receptor radionuclide therapy for neuroendocrine tumors, improving progression-free survival and quality of life
What the researchers found
PRRT with 177Lu-DOTATATE (approved 2017-2018) is an established treatment for somatostatin receptor-positive well-differentiated neuroendocrine neoplasms (NENs):
- Improves progression-free survival and quality of life in GEP NEN patients
- Shows favorable symptomatic and biochemical responses in functioning metastatic tumors including insulinomas, VIPomas, glucagonomas, and gastrinomas
- Being investigated as first-line therapy and in combination with cytotoxic drugs
- Expanding to bronchopulmonary NENs, pheochromocytomas, paragangliomas, and medullary thyroid carcinomas
Next-generation developments include somatostatin analog peptides coupled with alpha-emitting radionuclides (more potent radiation) and somatostatin receptor antagonists with radionuclides.
Why it matters
PRRT represents one of the most successful examples of peptide-based precision medicine — using a peptide's natural receptor-targeting ability to deliver radiation directly to cancer cells while sparing healthy tissue. Its 'theranostic' approach (same peptide for diagnosis and treatment) is a model for personalized cancer care.
How the study worked
This is a clinical review published in JCEM synthesizing published clinical trial data, approved indications, and emerging research on peptide receptor radionuclide therapy using radiolabeled somatostatin analogs.
What this study cannot tell us
PRRT is currently approved only as second/third-line therapy, not first-line. Not all neuroendocrine tumors express sufficient somatostatin receptors for effective targeting. Side effects include renal toxicity and bone marrow suppression. Long-term outcomes beyond progression-free survival need further study. First-line use and combination therapy data are still preliminary.
How to read the evidence
This is a clinical review published in a top endocrinology journal summarizing evidence from clinical trials, including the pivotal NETTER-1 trial that led to FDA approval. The underlying evidence for the approved indication is strong (Phase 3 RCT).
When this study was published
Published in 2022, this review reflects the established evidence base for PRRT and previews next-generation developments in radiolabeled peptide therapies.
The bigger picture
PRRT pioneered the theranostic concept that is now transforming oncology beyond neuroendocrine tumors. The success of somatostatin peptide-guided radiation has inspired similar approaches using other peptides (like PSMA-targeting agents for prostate cancer), establishing peptide-based theranostics as a growing paradigm in precision oncology.
Questions still open
- Will first-line PRRT prove superior to current standard treatments for newly diagnosed GEP NENs?
- Can alpha-emitting radionuclides overcome limitations of current beta-emitting 177Lu-DOTATATE?
- Will somatostatin receptor antagonists improve tumor targeting compared to current agonist-based approaches?
Common questions
How does peptide receptor radionuclide therapy work?
What is theranostics and why is it important?
Read the original research
Peptide Receptor Radionuclide Therapy.
The Journal of clinical endocrinology and metabolism, 107(12), 3199-3208
Citation
Hofland, Johannes; Brabander, Tessa; Verburg, Frederik A; Feelders, Richard A; de Herder, Wouter W. (2022). Peptide Receptor Radionuclide Therapy.. The Journal of clinical endocrinology and metabolism, 107(12), 3199-3208. https://doi.org/10.1210/clinem/dgac574